Actively Recruiting
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2018-05-30
480
Participants Needed
1
Research Sites
625 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical role in the development and progression of pancreatic cancer. Here we intend to assess the synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0 resection of pancreatic cancer.
CONDITIONS
Official Title
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old and above
- Surgery for R0 resection
- No prior gemcitabine chemotherapy for other malignancies
- Eastern Cooperative Oncology Group score between 0 and 2
- Neutrophil count at least 1.5 x 10^9/ml, platelet count at least 100 x 10^9/ml, hemoglobin at least 80 g/L
- Liver function: bilirubin ≤ 1.5 times upper limit of normal; alanine aminotransferase and aspartate aminotransferase ≤ 3 times upper limit
- Kidney function: creatinine ≤ 1.2 mg/dL
You will not qualify if you...
- Endocrine carcinoma, acinar pancreatic carcinoma, or cystadenocarcinoma
- Surgery for pancreatic cancer not meeting R0 resection criteria
- Prior radiotherapy for pancreatic cancer before surgery
- Malignant brain metastases
- History of other serious cancers
- Active infection or severe diarrhea
- Allergy or intolerance to celecoxib or related drugs such as aspirin or NSAIDs
- Pregnancy or breastfeeding
- Active gastrointestinal ulcer, hemorrhage, or perforation
- Severe mental illness
- Severe heart failure
- History of serious cardiovascular thrombotic events
- Severe hypertension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the second affiliated hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
T
Tingbo Liang
CONTACT
X
Xueli Bai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here